If we want data and clinical trials that meaningfully represent the population of people who take the drug, we’ll need to do more than just issue guides.
In this episode, we interview returning guest Kirsten Axelsen,Senior Advisor for Charles River Associates, about making medicine more accessible to lower income people and creating a more equitable health system with better data.
Join us as we discuss:
The detrimental effects of price controls on early life stages of drug development
Why a price control on one is a price control on all
The deep concerns about health disparity and equity
How data can address racism, ageism, and poverty in health systems
2022 as the year of the non-COVID vaccine



Check out these resources we mentioned:
Report referenced at 1:16 here and here.
Build Back Better Act 



As we continue this journey together, we want to hear from you, the listener. Email [email protected] or [email protected] what’s top of mind, what story you want to hear, or what you find interesting!
To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.
Listening on a desktop & can’t see the links? Just search for Making Medicine in your favorite podcast player.